Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Everest Medicines Ltd. (1952) Stock Price & Analysis

5 Followers

1952 Stock Chart & Stats

HK$26.24-HK$0.64(-2.38%)
At close: 4:00 PM GMT+8
HK$25HK$30HK$35Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 25.92 - HKD 26.90
52-Week Range
HKD 22.70 - HKD 50.30
Previous Close
HKD 26.88
Volume
N/A
Average Volume (3M)
5.07M
Market Cap
HKD 9.53B
Enterprise Value
HKD 8.57B
Total Cash (Recent Filing)
HKD 2.04B
Total Debt (Recent Filing)
HKD 1.99B
Price to Earnings (P/E)
―
Beta
0.96
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
2.17
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Rapid Revenue Growth

The near-doubling of revenue demonstrates strong commercial expansion and growing product adoption. If the company sustains this trajectory, increasing scale could improve operating leverage, strengthen its market position, and provide a broader base from which to reach profitability.

Healthy Gross Margin

A gross margin near 60% indicates attractive product-level economics and suggests revenue growth is not being purchased through structurally weak pricing. This creates potential for future operating leverage as commercial scale grows, provided the company can control operating expenses and development investment.

Moderate Leverage And Capital Base

Sizable equity and moderate leverage give Everest Medicines a comparatively resilient funding base for a biotechnology company. This financial capacity can support operations and growth initiatives while reducing near-term dependence on heavy borrowing, although continued losses could gradually consume capital.

Bears Say

Persistent Net Losses

Despite strong revenue growth and healthy gross margin, the company has not yet converted commercial expansion into sustainable profitability. Continued net losses can limit internally generated funding, weaken returns on invested capital, and make future earnings dependent on successful operating leverage.

Negative Operating And Free Cash Flow

The business remains unable to fund itself from operations, as both operating and free cash flow were negative in 2025. Although the burn rate improved substantially from 2024, persistent cash consumption can reduce financial flexibility and require existing resources or external financing to sustain growth.

Negative Returns On Equity

Repeatedly negative return on equity shows that shareholder capital has not yet generated positive returns and reflects the company’s continuing losses. If this pattern persists, capital may be consumed without a corresponding earnings contribution, constraining long-term value creation and allocation flexibility.

Everest Medicines Ltd. News

1952 FAQ

What was Everest Medicines Ltd.’s price range in the past 12 months?
Everest Medicines Ltd. lowest stock price was HK$22.70 and its highest was HK$50.30 in the past 12 months.
What is Everest Medicines Ltd.’s market cap?
Everest Medicines Ltd.’s market cap is HK$9.53B.
When is Everest Medicines Ltd.’s upcoming earnings report date?
Everest Medicines Ltd.’s next earnings report is estimated for Apr 01, 2027 (not yet confirmed), which is in 139 days.
How were Everest Medicines Ltd.’s earnings last quarter?
Everest Medicines Ltd. released its earnings results on Aug 18, 2026. The company reported -HK$0.023 earnings per share for the quarter, beating the consensus estimate of -HK$1.087 by HK$1.064.
Is Everest Medicines Ltd. overvalued?
According to Wall Street analysts Everest Medicines Ltd.’s price is currently Undervalued.
Does Everest Medicines Ltd. pay dividends?
Everest Medicines Ltd. does not currently pay dividends.
What is Everest Medicines Ltd.’s EPS estimate?
Everest Medicines Ltd.’s EPS estimate is 2.17.
How many shares outstanding does Everest Medicines Ltd. have?
Everest Medicines Ltd. has 354,639,220 shares outstanding.
What happened to Everest Medicines Ltd.’s price movement after its last earnings report?
Everest Medicines Ltd. reported an EPS of -HK$0.023 in its last earnings report, beating expectations of -HK$1.087. Following the earnings report the stock price went down -18.716%.
Which hedge fund is a major shareholder of Everest Medicines Ltd.?
Currently, no hedge funds are holding shares in HK:1952
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology